Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10627353 | 0.90 | MEN1 (0.34) | MEN1GLATSHRHTTKMT2A | |
| SCHEMBL1397057 | 0.75 | ALDH1A1 (0.39) | TSHR | |
| SCHEMBL10748182 | 0.68 | CSNK1A1 (0.36) | MEN1GLATSHRHTTKMT2A | |
| SCHEMBL10989493 | 0.66 | CDK1 (0.32) | TSHR | |
| Ammonia Solution, Strong SCHEMBL543592 | 0.65 | USP2 (0.39) | — | |
| SCHEMBL11021418 | 0.65 | CYP1A2 (0.36) | MEN1GLATSHRHTTKMT2A | |
| SCHEMBL10990838 | 0.63 | XDH (0.41) | MEN1HTTKMT2A | |
| SCHEMBL23889376 | 0.62 | — | — | |
| SCHEMBL9618980 | 0.62 | CSNK1A1 (0.40) | — | |
| SCHEMBL10990458 | 0.60 | GAA (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 852 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391729-B2 | Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria | SPOGEN BIOTECH INC. (US) | 2025-08-19 | — | — | US | claimed |
| US-20240199709-A1 | FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA | SPOGEN BIOTECH INC (US) | 2024-06-20 | — | — | US | claimed |
| US-11905315-B2 | Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria | SPOGEN BIOTECH INC. (US) | 2024-02-20 | — | — | US | claimed |
| US-20210179672-A1 | FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA | GENISYS CREDIT UNION | 2021-06-17 | — | — | US | claimed |
| EP-2533633-B1 | FUNGICIDAL MIXTURES | LANXESS DISTRIB GMBH (DE) | 2017-02-01 | — | — | EP | claimed |
| WO-2016044655-A2 | FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA | SPOGEN BIOTECH INC. (US) | 2016-03-24 | — | — | WO | claimed |
| US-20130195997-A1 | FUNGICIDAL MIXTURES | LANXESS DISTRIBUTION GMBH (DE) | 2013-08-01 | — | — | US | claimed |
| EP-2533633-A2 | FUNGICIDAL MIXTURES | LANXESS Distribution GmbH (DE) | 2012-12-19 | — | — | EP | claimed |
| EP-2460408-A1 | Nematicidal compositions | deVGen N.V. (BE) | 2012-06-06 | — | — | EP | claimed |
| US-20110319435-A1 | FUNGICIDE MIXTURES | LANXESS DISTRIBUTION GMBH (DE) | 2011-12-29 | — | — | US | claimed |
| WO-2011095492-A2 | FUNGICIDAL MIXTURES | LANXESS DISTRIBUTION GMBH (DE) | 2011-08-11 | — | — | WO | claimed |
| EP-2315522-A2 | FORMATE-CONTAINING FUNGICIDE MIXTURES | LANXESS Distribution GmbH (DE) | 2011-05-04 | — | — | EP | claimed |
| EP-2153720-A1 | Fungicide mixtures comprising formate | LANXESS Distribution GmbH (DE) | 2010-02-17 | — | — | EP | claimed |
| WO-2010015635-A2 | FUNGICIDE MIXTURES | LANXESS DISTRIBUTION GMBH (DE) | 2010-02-11 | — | — | WO | claimed |
| JP-60193970-A | — | — | None | — | — | JP | disclosed |
| US-12630484-B2 | Methods for promoting plant health using free enzymes and microorganisms that overexpress enzymes | SPOGEN BIOTECH INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12599649-B2 | Bioactive polypeptides for improvements in plant protection, growth and productivity | SPOGEN BIOTECH INC. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-0244193-A2 | Dihalogen-substituted thiocyanopyrimidine derivatives | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1987-11-04 | — | — | EP | disclosed |
| US-4652569-A | Thiocyanopyrimidine, agricultural and horticultural fungicide containing same | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1987-03-24 | — | — | US | disclosed |
| JP-S60193970-A | THIOCYANOPYRIMIDINE DERIVATIVE, ITS PREPARATION AND FUNGICIDE FOR AGRICULTURAL AND HORTICULTURAL PURPOSES | MITSUI TOATSU CHEM INC | 1985-10-02 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630484-B2 | Methods for promoting plant health using free enzymes and microorganisms that overexpress enzymes | ADA, RNGTT, GNPDA1 | MEN1 3413/4885GLA 307/4885TSHR 1810/4885 |
| US-12599649-B2 | Bioactive polypeptides for improvements in plant protection, growth and productivity | MAX, VIP, MRTO4 | MEN1 3270/4885GLA 199/4885TSHR 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.